Microcirculation Inflammation Associates With Outcome in Renal Transplant Patients With De Novo Donor-Specific Antibodies

被引:90
作者
de Kort, H. [1 ]
Willicombe, M. [2 ]
Brookes, P. [3 ]
Dominy, K. M. [1 ]
Santos-Nunez, E. [3 ]
Galliford, J. W. [2 ]
Chan, K. [2 ]
Taube, D. [2 ]
McLean, A. G. [2 ]
Cook, H. T. [1 ]
Roufosse, C. [1 ]
机构
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Histopathol, London, England
[2] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Imperial Coll Kidney & Transplant Ctr, London, England
[3] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Histocompatibil & Immunogenet Lab, London, England
关键词
Antibody-mediated rejection; C4d; donor-specific antibodies; histopathology; microcirculation inflammation; renal transplantation; ACUTE HUMORAL REJECTION; HLA ANTIBODIES; KIDNEY-TRANSPLANT; MEDIATED REJECTION; ALLOGRAFT PATHOLOGY; GRAFT FAILURE; RECIPIENTS; CLASSIFICATION; BIOPSIES;
D O I
10.1111/j.1600-6143.2012.04325.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
In renal transplant patients with de novo donor-specific antibodies (dnDSA) we studied the value of microcirculation inflammation (MI; defined by the addition of glomerulitis (g) and peritubular capillaritis (ptc) scores) to assess long-term graft survival in a retrospective cohort study. Out of all transplant patients with standard immunological risk (n = 638), 79 (12.4%) developed dnDSA and 58/79 (73%) had an indication biopsy at or after dnDSA development. Based on the MI score on that indication biopsy patients were categorized, MI0 (n = 26), MI1?+?2 (n = 21) and MI?=?3 (n = 11). The MI groups did not differ significantly pretransplantation, whereas posttransplantation higher MI scores developed more anti-HLA class I?+?II DSA (p?= 0.011), showed more TCMR (p?<?0.001) and showed a trend to C4d-positive staining (p = 0.059). Four-year graft survival estimates from time of indication biopsy were MI0 96.1%, MI1?+?2 76.1% and MI?=?3 17.1%; resulting in a 24-fold increased risk of graft failure in the MI?=?3 compared to the MI0 group (p = 0.003; 95% CI [3.0196.0]). When adjusted for C4d, MI?=?3 still had a 21-fold increased risk of graft failure (p = 0.005; 95% CI [2.5180.0]), while C4d positivity on indication biopsy lost significance. In renal transplant patients with de novo DSA, microcirculation inflammation, defined by g?+?ptc, associates with graft survival.
引用
收藏
页码:485 / 492
页数:8
相关论文
共 50 条
  • [41] Influence of de novo donor-specific antibody on early renal allograft function recovery
    Zheng, Jin
    Xue, Wujun
    Jing, Xin
    Hou, Jun
    Tian, Xiaohui
    Tian, Puxun
    Ding, Xiaoming
    Pan, Xiaoming
    Yan, Hang
    Feng, Xinshun
    Xiang, Heli
    Li, Yang
    Ding, Chenguang
    RENAL FAILURE, 2015, 37 (03) : 462 - 468
  • [42] Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients
    Solomon, Sonia
    Colovai, Adriana
    Del Rio, Marcela
    Hayde, Nicole
    PEDIATRIC NEPHROLOGY, 2020, 35 (02) : 261 - 270
  • [43] Testing for donor-specific antibodies in renal transplantation: Indian perspective
    Etta, Praveen Kumar
    INDIAN JOURNAL OF TRANSPLANTATION, 2020, 14 (02) : 90 - 93
  • [44] Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation
    Islam, Ana K.
    Sinha, Neeraj
    DeVos, Jennifer M.
    Kaleekal, Thomas S.
    Jyothula, Soma S.
    Teeter, Larry D.
    Nguyen, Duc T. M.
    Eagar, Todd N.
    Moore, Linda W.
    Puppala, Mamta
    Wong, Stephen T. C.
    Knight, Richard J.
    Frost, Adaani E.
    Graviss, Edward A.
    Gaber, A. Osama
    CLINICAL TRANSPLANTATION, 2017, 31 (08)
  • [45] Many de novo donor-specific antibodies recognize β2-microglobulin-free, but not intact HLA heterodimers
    Michel, K.
    Santella, R.
    Steers, J.
    Sahajpal, A.
    Downey, F. X.
    Thohan, V.
    Oaks, M.
    HLA, 2016, 87 (05) : 356 - 366
  • [46] Age-associated decrease in de novo donor-specific antibodies in renal transplant recipients reflects changing humoral immunity
    von Moos, Seraina
    Schalk, Gesa
    Mueller, Thomas F.
    Laube, Guido
    IMMUNITY & AGEING, 2019, 16
  • [47] Reducing De Novo Donor-Specific Antibody Levels during Acute Rejection Diminishes Renal Allograft Loss
    Everly, M. J.
    Everly, J. J.
    Arend, L. J.
    Brailey, P.
    Susskind, B.
    Govil, A.
    Rike, A.
    Roy-Chaudhury, P.
    Mogilishetty, G.
    Alloway, R. R.
    Tevar, A.
    Woodle, E. S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) : 1063 - 1071
  • [48] Incidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts
    Everly, Matthew J.
    Rebellato, Lorita M.
    Haisch, Carl E.
    Ozawa, Miyuki
    Parker, Karen
    Briley, Kimberly P.
    Catrou, Paul G.
    Bolin, Paul
    Kendrick, William T.
    Kendrick, Scott A.
    Harland, Robert C.
    Terasaki, Paul I.
    TRANSPLANTATION, 2013, 95 (03) : 410 - 417
  • [49] Molecular signatures and clinical outcomes of transplant glomerulopathy stratified by microvascular inflammation and donor-specific antibody
    Lubetzky, Michelle
    Hayde, Nicole
    Broin, Pilib O.
    Ajaimy, Maria
    Bao, Yi
    Mohammed, Omar
    Schwartz, Daniel
    Pullman, James
    Akalin, Enver
    CLINICAL TRANSPLANTATION, 2019, 33 (03)
  • [50] Results of early treatment for de novo donor-specific antibodies in pediatric kidney transplant recipients in a cross-sectional and longitudinal cohort
    Charnaya, Olga
    Tuchman, Shamir
    Moudgil, Asha
    PEDIATRIC TRANSPLANTATION, 2018, 22 (02)